Enfusion, Inc. (ENFN)
NYSE: ENFN · IEX Real-Time Price · USD
9.42
+0.12 (1.29%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Enfusion Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Enfusion stock have an average target of 9.33, with a low estimate of 8.00 and a high estimate of 11. The average target predicts a decrease of -0.96% from the current stock price of 9.42.
Analyst Consensus: Sell
* Price targets were last updated on Mar 13, 2024.
Analyst Ratings
The average analyst rating for Enfusion stock from 6 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 3 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 6 | 6 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Sell Maintains $8 → $9 | Sell | Maintains | $8 → $9 | -4.46% | Mar 13, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $9 → $8 | Hold → Strong Sell | Downgrades | $9 → $8 | -15.07% | Feb 28, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades $11 → $9 | Hold → Sell | Downgrades | $11 → $9 | -4.46% | Jan 30, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $9 → $10 | Hold | Maintains | $9 → $10 | +6.16% | Dec 20, 2023 |
| UBS | UBS | Hold Initiates $9 | Hold | Initiates | $9 | -4.46% | Nov 7, 2023 |
Financial Forecast
Revenue This Year
209.69M
from 174.54M
Increased by 20.14%
Revenue Next Year
248.09M
from 209.69M
Increased by 18.31%
EPS This Year
0.22
from 0.07
Increased by 218.75%
EPS Next Year
0.31
from 0.22
Increased by 37.14%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 220.5M | 265.7M | 314.8M |
| Avg | 209.7M | 248.1M | 290.2M |
| Low | 200.1M | 233.1M | 268.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 26.3% | 26.7% | 26.9% |
| Avg | 20.1% | 18.3% | 17.0% |
| Low | 14.6% | 11.2% | 8.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.27 | 0.39 | 0.38 |
| Avg | 0.22 | 0.31 | 0.32 |
| Low | 0.15 | 0.21 | 0.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 290.0% | 74.1% | 23.5% |
| Avg | 218.8% | 37.1% | 5.6% |
| Low | 110.0% | -7.8% | -7.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.